Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06145802 | Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors) | withdrawn | N/A | 0 | Grit BiotechnologyINDUSTRY | 0 | Apr 29, 2026 | clinicaltrials |
| NCT06927687 | Study of ZG005 in Patients With Advanced Solid Tumors | active not recruiting | Phase 2 | 50 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07058948 | Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors(SFRT-IM-P2) | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07556276 | Study of CMTS1215 Injection in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 20 | The Second Hospital of Nanjing Medical UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03964727 | Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors(TROPiCS-03) | active not recruiting | Phase 2 | 227 | Gilead SciencesINDUSTRY | 8 | Apr 28, 2026 | clinicaltrials |
| NCT04483778 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 68 | Seattle Children's HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05451602 | HEC169096 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 456 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05687682 | Safety of AM-928 Infusion in Advanced Solid Tumors | recruiting | Phase 1 | 38 | AcadeMab Biomedical Inc.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06010342 | A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients | recruiting | Phase 2 | 60 | Teligene USINDUSTRY | 2 | Apr 28, 2026 | clinicaltrials |
| NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body(BrILliance) | recruiting | Phase 1 / Phase 2 | 240 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | terminated | Phase 2 | 6 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07258121 | Study of ZGGS34 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07413328 | HWS116 Monotherapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 56 | Wuhan Humanwell Innovative Drug Research and Development Center Limited CompanyINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07554196 | A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors | completed | Phase 1 | 12 | Huahui HealthINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04650178 | Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials | active not recruiting | — | 274 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05430360 | Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors(GT201) | terminated | Phase 1 | 2 | Grit BiotechnologyINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05660421 | Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors | withdrawn | Phase 2 | 0 | Douglas JohnsonOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT05729399 | Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 6 | Grit BiotechnologyINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06132828 | Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 216 | Zhejiang Doer Biologics Co., Ltd.INDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06227377 | QTX3034 in Patients With KRAS G12D Mutation | recruiting | Phase 1 | 250 | Quanta TherapeuticsINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06723236 | A Study of MGC028 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 124 | MacroGenicsINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07439094 | A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 140 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04829539 | Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment(BBT-II) | active not recruiting | Phase 3 | 400 | University of Rochester NCORP Research BaseOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06801002 | Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies | recruiting | Phase 1 | 25 | Jabez Bioscience, IncINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06816992 | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC | recruiting | Phase 1 | 76 | ORIC PharmaceuticalsINDUSTRY | 3 | Apr 24, 2026 | clinicaltrials |
| NCT01787500 | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | completed | Phase 1 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02661542 | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 106 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03810339 | Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors | recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05951608 | A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 216 | AkesoINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06308263 | Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) | completed | Phase 1 | 12 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07541001 | PRL3-Zumab in Patients With Advanced Solid Tumors(China Phase II) | active not recruiting | Phase 2 | 60 | Intra-IMMUSG Pte LtdINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07541573 | GTB-5550 in Advanced Solid Tumors | recruiting | Phase 1 | 175 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04452955 | A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 51 | Intra-IMMUSG Pte LtdINDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05036291 | A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors | terminated | Phase 1 | 25 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT05858424 | Impact of a Multidisciplinary End-of-treatment Day Hospital on the Quality of Life of Adolescents and Young Adults With Cancer(HOPAYA) | recruiting | N/A | 214 | Centre Leon BerardOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06779851 | A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors(SUMMIT-1) | terminated | Phase 1 | 20 | Bright Peak Therapeutics IncINDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT07545486 | Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment(ATOM-1st) | not yet recruiting | — | 1,235 | ChirecOTHER | 5 | Apr 22, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT06532565 | Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 154 | Gilead SciencesINDUSTRY | 2 | Apr 21, 2026 | clinicaltrials |
| NCT07346846 | A Study of BGM-2121 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 35 | BioGate Precision Medicine Corp.INDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07542704 | A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies | not yet recruiting | Phase 1 | 48 | Kumquat Biosciences Inc.INDUSTRY | 0 | Apr 21, 2026 | clinicaltrials |
| NCT01281176 | High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02041416 | Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers | active not recruiting | — | 100 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02517034 | Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer | active not recruiting | N/A | 600 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06326411 | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors(NST-628) | recruiting | Phase 1 | 230 | Nested Therapeutics, IncINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT06892379 | A Study of HS-20110 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 475 | Hansoh BioMedical R&D CompanyINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT07539285 | A Study of HDM2024 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 63 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 29, 2026source: clinicaltrials